Assessing the future of solid tumor immunotherapy
P Guha, KR Heatherton, KP O'Connell, IS Alexander… - Biomedicines, 2022 - mdpi.com
With the advent of cancer immunotherapy, there has been a major improvement in patient's
quality of life and survival. The growth of cancer immunotherapy has dramatically changed …
quality of life and survival. The growth of cancer immunotherapy has dramatically changed …
Single‐cell sequencing combined with spatial transcriptomics reveals that the IRF7 gene in M1 macrophages inhibits the occurrence of pancreatic cancer by …
T Zhan, Y Zou, Z Han, XR Tian, M Chen… - Clinical and …, 2024 - Wiley Online Library
Aim The main focus of this study is to explore the molecular mechanism of IRF7 regulation
on RPS18 transcription in M1‐type macrophages in pancreatic adenocarcinoma (PAAD) …
on RPS18 transcription in M1‐type macrophages in pancreatic adenocarcinoma (PAAD) …
[HTML][HTML] Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model
BA Capacio, JSS Narayanan, DA Vicente, Y Liu… - Surgery, 2023 - Elsevier
Background Systemic immunotherapy has had limited clinical benefit in pancreatic ductal
adenocarcinoma. This is thought to be due to its desmoplastic immunosuppressive tumor …
adenocarcinoma. This is thought to be due to its desmoplastic immunosuppressive tumor …
Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthotopic murine pancreatic cancer model
JSN Shankara Narayanan, K Frizzi, S Erdem, P Ray… - Discover Oncology, 2022 - Springer
Purpose There is a great need to reduce the toxicity of chemotherapy used in the
management of pancreatic ductal adenocarcinoma (PDAC). Here we explore if regional …
management of pancreatic ductal adenocarcinoma (PDAC). Here we explore if regional …